Latest India Pesticides News
Comprehensive India Pesticides Stock Updates: Catch up on the latest India Pesticides stock news and industry insights. Get quick details on India Pesticides stock buybacks,India Pesticides results, India Pesticides company analysis, India Pesticides live prices, India Pesticides dividends, India Pesticides bonus share, board meetings, lifetime highs, India Pesticides targets, lows, and growth stories with AI.
The Economic Times
Video on demand category generated $1.04 billion in revenues during H1 2024
The premium video-on-demand market in India saw a significant rise in the first half of 2024, generating $1.04 billion in revenues. Local content, especially live sports and dramas, drove engagement. Jio Cinema, Netflix, and Disney+ Hotstar led the revenue charts, with cricket events like IPL and ICC World Cup boosting viewership.
•
Thu, Sep 19, 2024
Business Standard
Hero Moto, Cipla, NTPC: Stock picks by Chandan Taparia for today, Sept 18
Stocks to buy today: The stock of Hero MotoCorp has given a range breakout on daily scale with noticeable volumes
•
Wed, Sep 18, 2024
The Economic Times
Cipla Stocks Live Updates: Cipla Closes at Rs 1659.70 with Volume Below Weekly Average
undefined
•
Mon, Sep 16, 2024
The Economic Times
The Indian Double League: Power play revenues of top IPL franchises rise 2x in FY24
The Indian Premier League (IPL) franchises more than doubled their revenues for the year ended March 2024, thanks to increased share from the league’s central revenue pool during IPL 2023. The collective earnings of the 10 teams surged, with significant profitability improvements driven by a new media rights deal and sponsorship agreements.
The Economic Times
IPL franchise powers Sun TV's FY24 revenue growth amid challenges in TV business
The company's revenue from cricket franchises surged by 138% to Rs 659 crore in FY24, up from Rs 276 crore in the previous year. The company's consolidated revenue from operations surged 15% to Rs 4,787 crore, while net profit jumped 13% to Rs 1,925 crore.
•
Wed, Sep 4, 2024
The Economic Times
As M&A scene hots up, India Inc strengthens in-house legal teams
Large Indian conglomerates are strengthening their in-house legal teams with M&A specialists due to a surge in local and cross-border deals. Companies like Reliance Industries, Cipla, and Aditya Birla Group are hiring experienced lawyers to reduce reliance on external counsel and enhance transaction efficiency.
•
Wed, Sep 4, 2024
Business Line
Change at Cipla, as MK Hamied resigns and son Kamil re-enters the drugmaker
The developments involving Cipla’s promoter family come even as reports suggested, as recently as last year, that members of the promoter family were looking to sell their stake
•
Wed, Sep 4, 2024
CNBC TV18
Abbott India, Cipla, Biocon may get some relief from the GST Council: Exclusive
Sources further said that the GST council nominated fitment committee is likely to reduce GST on cancer drugs like Trastuzumab Deruxtecan, Osimertinib, Durvalumab to 5% from the current levels of 12%.
•
Wed, Sep 4, 2024
Business Line
IPL valuation dips 10.6% to ₹82,700 crore due to demand-side constraints: D&P Advisory report
Downturn in IPL valuation comes despite the league continuing to attract audiences across TV and digital platforms, says the report
•
Wed, Sep 4, 2024
Mint
Stocks to Watch: AU Small Finance Bank, GIC, Zee, Cipla, SpiceJet, KIMS, and more
Here’s a quick look at stocks likely to be in focus in today's trade.
•
Wed, Sep 4, 2024
Business Line
Stocks that will see action today: September 4, 2024
Buzzing stocks: Raymond, IEX, GIC-RE, Utkarsha SFB, AU SFB, Rane Holdings, Finolex Cables, Cipla, Godrej Phillips, Zee Entertainment, NHPC, GSK Pharma
•
Wed, Sep 4, 2024
Mint
Cipla's MK Hamied steps down after 47 years of service from company citing 'age and health' reasons
Cipla Ltd., a leading pharmaceutical company, announced the retirement of its Vice Chairman and Non-Executive Director, MK Hamied, after a tenure spanning 47 years.
•
Wed, Sep 4, 2024
Hindustan Times
Cipla's vice-chairman MK Hamied resigns citing age, his son Kamil to join board
Cipla's MK Hamied resigned due to age and health. Kamil Hamied is appointed as Non-Executive Director starting November 1, 2024.
•
Wed, Sep 4, 2024
The Economic Times
IPL valuation down by 11.7% on weak media rights score
The Indian Premier League's (IPL) business value has decreased by 11.7% to $9.9 billion in 2024 due to a reassessment of media rights and industry consolidation. The merger between Star India and Viacom18, along with the delay in tech giants entering the bidding, has contributed to this decline.
Business Standard
MK Hamied steps down as Cipla's Vice Chairman on account of age, health
Drug major Cipla on Tuesday said MK Hamied has resigned as Vice Chairman with effect from October 29 due to age and health. "It is with a heavy heart that I write to formally announce my resignation from the position of Vice Chairman and Non-Executive Director of the company," he said in a letter to the board of directors. The company said the board has also approved the appointment of Kamil Hamied as Non-Executive Director, with effect November 1, 2024. "I am pleased to see that Kamil Hamied will be joining the Board as a Non-Executive Director to maintain continuity while representing the promoter family," MK Hamied said in the letter.
•
Tue, Sep 3, 2024
The Economic Times
Cipla's vice-chairman MK Hamied resigns citing age and health, his son Kamil to join the board
Cipla's vice-chairman MK Hamied has resigned from the board due to age and health concerns, effective October 29, 2024. His son Kamil Hamied will join as a non-executive director from November 1, 2024. Cipla also appointed Adil Zainulbhai and Abhijit Joshi as additional directors starting September 3, 2024.
•
Tue, Sep 3, 2024
CNBC TV18
MK Hamied resigns as Cipla vice chairman; Kamil Hamied to join as non-executive director
MK Hamied has resigned as Vice Chairman of Cipla, effective 29th October 2024, citing age and health reasons. Kamil Hamied will join the Board as a Non-Executive Director from 1st November 2024, ensuring continuity in leadership.
•
Tue, Sep 3, 2024
The Economic Times
Cipla's MK Hamied resigns from the company due to health reasons
Cipla's Vice Chairman and Non-Executive Director, Mr. M K Hamied, has resigned from his position due to age and health reasons. His resignation will be effective from the close of business hours on October 29, 2024. In a letter to employees, Hamied expressed pride in his tenure and confidence in Cipla's future success.
•
Tue, Sep 3, 2024
Business Line
Cipla management outlines new focus areas for the future
Promoter stake sale this year was towards social efforts, management tells shareholders
•
Mon, Sep 2, 2024
The Economic Times
Star India’s merger with RIL's Viacom18: How Disney's financials may get a lift
The proposed merger between Star India and Viacom18, approved by the Competition Commission of India (CCI), will benefit Walt Disney by alleviating financial strains from its Indian operations. After the merger, Disney will hold a 37% stake in the new entity, while Reliance Industries will control 56% and Bodhi Tree Systems will have 7%. This shift means Disney won't need to report Indian financial losses, which have impacted its global performance. Star India's sports and streaming ventures, including costly IPL and ICC media rights, have contributed to heavy losses, whereas Disney's ESPN remains profitable.
•
Thu, Aug 29, 2024
The Economic Times
F&O stocks to buy today: ONGC, Cipla among top 9 trading ideas for 13 August 2024
The Indian market was poised for consolidation due to mixed global influences. FIIs registered substantial sales while DIIs made significant purchases. Focus was on key index levels and stock picks for short-term trading, including Cipla, Hindustan Unilever, and ONGC, with specific targets and stop-losses provided by experts.
•
Tue, Aug 13, 2024
Business Line
Cipla gets ₹773-crore I-T notice
Drugmaker Cipla says it would appeal the order
•
Tue, Jul 16, 2024
The Economic Times
Cipla gets Rs 773 crore demand notice from I-T department
The additional demand was raised for disallowances related to deduction of profits and gains derived from the business of developing, maintaining, and operating the infrastructure facilities, expenditure on R&D, business or professional expenses.
•
Tue, Jul 16, 2024
The Economic Times
T20 World Cup triumph sends Indian players' valuation soaring
The commercial value of India's T20 World Cup winning team is expected to soar into billions, surpassing the IPL's brand worth. Key players like Hardik Pandya, Jasprit Bumrah, and Surya Kumar Yadav are set to see a significant increase in their market valuation.
•
Sun, Jun 30, 2024
Business Standard
Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam
Orchid Pharma said that it has partnered with Cipla to ensure widespread and rapid distribution of the company's new drug- Cefepime-Enmetazobactam across India.
•
Sat, Jun 29, 2024
Business Line
Orchid Pharma ties up with Cipla for new UTI drug’s distribution
It is estimated that the drug sales could reach an annual value of about ₹100 crore, in about 2-3 years
•
Fri, Jun 28, 2024
Business Standard
Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India
Orchid Pharma announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications.
•
Fri, Jun 28, 2024
Business Standard
Orchid Pharma join hands with Cipla to launch new antibiotic in India
The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence
•
Fri, Jun 28, 2024
Business Line
Stocks that will see action today: June 24, 2024
Buzzing stocks: Car Trade, GRSE, IREDA, Maruti Suzuki, Cipla, Lupin, TVS Motor, JSW Energy, Prestige Estates, Optiemus Infracom, Inox Gree, Capacite Infra, SP Apparels, Arihant Capital, Blue Cloud, Vama Ind
The Economic Times
Sun Pharma and Cipla have entered a licensing deal with Takeda Pharmaceutical to commercialize Vonoprazan tablets in India. This novel drug, used to treat Gastroesophageal Reflux Disease (GERD) and related acid disorders, will be marketed by Sun Pharma as Voltapraz and by Cipla under their own brands.
•
Fri, Jun 21, 2024
The Economic Times
Cipla makes additional investment in German mRNA biotech
Ethris' has four potential drugs under development pipeline, of which one is for treating uncontrolled asthma and three other for primary ciliary dyskinesia - a rare yet chronic respiratory disease. During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.
•
Tue, Jun 18, 2024
The Economic Times
Pitch report: IPL is a growing brand
American investment bank Houlihan Lokey has issued the 2024 IPL Brand Valuation Study, its comprehensive report into the business enterprise and brand values of the Indian Premier League (IPL)
•
Wed, Jun 12, 2024